JP2021522242A5 - - Google Patents

Info

Publication number
JP2021522242A5
JP2021522242A5 JP2020559394A JP2020559394A JP2021522242A5 JP 2021522242 A5 JP2021522242 A5 JP 2021522242A5 JP 2020559394 A JP2020559394 A JP 2020559394A JP 2020559394 A JP2020559394 A JP 2020559394A JP 2021522242 A5 JP2021522242 A5 JP 2021522242A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
ring
nitrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020559394A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522242A (ja
JP7304892B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/028607 external-priority patent/WO2019209759A1/en
Publication of JP2021522242A publication Critical patent/JP2021522242A/ja
Publication of JP2021522242A5 publication Critical patent/JP2021522242A5/ja
Priority to JP2023092450A priority Critical patent/JP2023101824A/ja
Application granted granted Critical
Publication of JP7304892B2 publication Critical patent/JP7304892B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020559394A 2018-04-24 2019-04-23 抗増殖性化合物およびその使用 Active JP7304892B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023092450A JP2023101824A (ja) 2018-04-24 2023-06-05 抗増殖性化合物およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862661719P 2018-04-24 2018-04-24
US62/661,719 2018-04-24
PCT/US2019/028607 WO2019209759A1 (en) 2018-04-24 2019-04-23 Antiproliferation compounds and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023092450A Division JP2023101824A (ja) 2018-04-24 2023-06-05 抗増殖性化合物およびその使用

Publications (3)

Publication Number Publication Date
JP2021522242A JP2021522242A (ja) 2021-08-30
JP2021522242A5 true JP2021522242A5 (https=) 2022-04-13
JP7304892B2 JP7304892B2 (ja) 2023-07-07

Family

ID=66655429

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020559394A Active JP7304892B2 (ja) 2018-04-24 2019-04-23 抗増殖性化合物およびその使用
JP2023092450A Pending JP2023101824A (ja) 2018-04-24 2023-06-05 抗増殖性化合物およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023092450A Pending JP2023101824A (ja) 2018-04-24 2023-06-05 抗増殖性化合物およびその使用

Country Status (27)

Country Link
US (4) US10815225B2 (https=)
EP (2) EP3784666B1 (https=)
JP (2) JP7304892B2 (https=)
KR (1) KR102813581B1 (https=)
CN (1) CN112236428B (https=)
AR (1) AR114496A1 (https=)
AU (1) AU2019261308B2 (https=)
BR (1) BR112020020940A2 (https=)
CA (1) CA3098335A1 (https=)
CY (1) CY1125433T1 (https=)
DK (2) DK4043460T3 (https=)
ES (2) ES2987356T3 (https=)
FI (1) FI4043460T3 (https=)
HR (2) HRP20241163T1 (https=)
HU (2) HUE058746T2 (https=)
IL (2) IL278142B2 (https=)
LT (1) LT3784666T (https=)
MX (1) MX2020011089A (https=)
PL (2) PL3784666T3 (https=)
PT (2) PT3784666T (https=)
RS (1) RS63281B1 (https=)
SG (1) SG11202009500QA (https=)
SI (1) SI3784666T1 (https=)
SM (1) SMT202200308T1 (https=)
TW (1) TWI813673B (https=)
WO (1) WO2019209759A1 (https=)
ZA (1) ZA202006071B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20241163T1 (hr) 2018-04-24 2024-11-22 Merck Patent Gmbh Antiproliferacijski spojevi i njihova uporaba
WO2020010451A1 (en) * 2018-07-10 2020-01-16 Trillium Therapeutics Inc. Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists
WO2020236834A1 (en) * 2019-05-20 2020-11-26 Seshadri Raju Modified z stents for iliac vein stenting
CN118496197A (zh) 2019-12-20 2024-08-16 拜耳公司 取代的噻吩甲酰胺、噻吩甲酸及其衍生物
WO2024073502A1 (en) * 2022-09-28 2024-04-04 Accutar Biotechnology Inc. Heterocyclic compounds as e3 ligase inhibitors
TW202547516A (zh) * 2024-04-26 2025-12-16 大陸商正大天晴藥業集團股份有限公司 稠合雙環化合物及其用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
DE19840028A1 (de) 1998-09-02 2000-03-09 Max Planck Gesellschaft Nucleinsäuremoleküle codierend Enzyme, die Fructosyltransferaseaktivität besitzen, und deren Verwendung
DE60037345T2 (de) 1999-12-10 2008-11-13 Pfizer Products Inc., Groton Pyrrolo(2,3-d)pyrimidin-Verbindungen
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
DE60217322T2 (de) 2001-04-27 2007-10-04 Zenyaku Kogyo K.K. Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
PT1536827E (pt) 2002-08-14 2009-03-20 Silence Therapeutics Ag Utilização de proteína cinase n beta
AU2004228668B2 (en) 2003-04-03 2011-10-27 Park Funding, Llc PI-3 kinase inhibitor prodrugs
ES2382377T3 (es) 2003-05-30 2012-06-07 Gemin X Pharmaceuticals Canada Inc. Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer
EP1692153A4 (en) 2003-07-03 2007-03-21 Univ Pennsylvania INHIBITION OF EXPRESSION OF SYK-KINASE
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
AU2006206458B2 (en) 2005-01-19 2012-10-25 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
PL1888550T3 (pl) 2005-05-12 2014-12-31 Abbvie Bahamas Ltd Promotory apoptozy
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
US7989622B2 (en) 2005-10-07 2011-08-02 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use
JP5191391B2 (ja) 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2007129161A2 (en) 2006-04-26 2007-11-15 F. Hoffmann-La Roche Ag Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
KR101566840B1 (ko) 2007-03-12 2015-11-06 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도
WO2008118802A1 (en) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Therapeutic compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
HUE029767T2 (en) 2008-03-11 2017-04-28 Incyte Holdings Corp JAK inhibitor azetidine and cyclobutane derivatives
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
DE102008031517A1 (de) * 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
CA2729045A1 (en) 2008-07-31 2010-02-04 Philippe Bergeron Pyrimidine compounds, compositions and methods of use
AR076014A1 (es) 2009-04-02 2011-05-11 Sanofi Aventis Derivados de 3- (1,4) oxazepan -4-pirimidona
BR112012012905A2 (pt) * 2009-12-04 2017-03-01 Hoffmann La Roche derivados de difenil azepina como inibidores da reabsorção de monoamina
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP3256132A1 (en) * 2015-02-13 2017-12-20 Merck Patent GmbH Pyrimidine derivatives for use in the treatment of cancer
HRP20241163T1 (hr) 2018-04-24 2024-11-22 Merck Patent Gmbh Antiproliferacijski spojevi i njihova uporaba

Similar Documents

Publication Publication Date Title
JP2021522242A5 (https=)
JP2023511337A5 (https=)
JP2021522237A5 (https=)
AR044403A1 (es) Derivados de oximas y su uso como inmunodepresores. composiciones farmaceuticas que los contienen.
JP2018536648A5 (https=)
JP2022538228A5 (https=)
PE20220597A1 (es) Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos
JP2015532295A5 (https=)
EA201990902A1 (ru) Ингибиторы тирозинкиназы брутона
HRP20220710T1 (hr) Antiproliferacijski spojevi i njihova uporaba
JP2018535963A5 (https=)
AR084976A1 (es) Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
JP2022514315A5 (https=)
CL2013002690A1 (es) Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer.
JP2020510091A5 (https=)
SI2743266T1 (en) Protein kinase inhibitors (variants), their use in the treatment of oncological diseases and the pharmaceutical composition on their basis
JP2020506951A5 (https=)
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
JP2023520330A5 (https=)
JP2016505586A5 (https=)
JP2017518959A5 (https=)
JP2022505645A5 (https=)
RU2012109554A (ru) Лиганды сигма-рецепторов для предупреждения или лечения боли, вызванной химиотерапией
JP2008517923A5 (https=)